Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 31 December, 2024
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo

Marksans Pharma Ltd: Fundamental Analysis, Share Price Insights & Intrinsic Value (2024)

Share Price and Basic Stock Data

Last Updated: December 31, 2024, 8:16 am

Market Cap 13,042 Cr.
Current Price 288
High / Low 359/126
Stock P/E37.7
Book Value 50.3
Dividend Yield0.21 %
ROCE20.6 %
ROE16.5 %
Face Value 1.00
PEG Ratio1.99

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Marksans Pharma Ltd

Competitors of Marksans Pharma Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
MPS Pharmaa Ltd 8.05 Cr. 4.21 4.33/2.79 0.800.00 %9.15 %34.9 % 10.0
Gujarat Themis Biosyn Ltd 3,274 Cr. 300 390/17062.1 20.50.22 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 62.3 Cr. 83.9 94.9/27.023.8 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 35.4 Cr. 24.2 27.0/8.7446.0 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 84.3 Cr. 112 155/87.012.6 55.40.00 %14.4 %15.5 % 10.0
Industry Average19,528.12 Cr1,193.9155.65184.740.31%16.14%16.48%6.30

All Competitor Stocks of Marksans Pharma Ltd

Quarterly Result

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales356358330349361363418434453480486500531
Expenses273267235272301305354361372403376398417
Operating Profit83919577605864738077110102114
OPM %23%25%29%22%17%16%15%17%18%16%23%20%21%
Other Income4-36691215161418111019
Interest2231215232222
Depreciation199177921111413141418
Profit before tax6678977560605376787910497114
Tax %23%24%18%16%23%20%44%21%23%21%21%27%26%
Net Profit51598063464830606062837084
EPS in Rs1.241.441.941.531.111.180.691.461.511.571.811.521.84

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales3564386307978937679131,0001,1341,3761,4911,8522,103
Expenses4553695126127577228348689421,0371,2321,5131,645
Operating Profit-100691181851364578132192340259340458
OPM %-28%16%19%23%15%6%9%13%17%25%17%18%22%
Other Income2443978507425945
Interest54151916107101098899
Depreciation24161616283027232736455267
Profit before tax-17544861561071550104157302248338427
Tax %-1%-12%15%28%23%24%28%23%23%21%25%21%
Net Profit-176497411283113680121239187265320
EPS in Rs1.191.872.671.920.220.801.872.955.834.515.887.01
Dividend Payout %-0%10%5%4%21%23%6%3%3%4%6%9%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2012-20132013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)127.84%51.02%51.35%-25.89%-86.75%227.27%122.22%51.25%97.52%-21.76%41.71%
Change in YoY Net Profit Growth (%)0.00%-76.82%0.33%-77.24%-60.85%314.02%-105.05%-70.97%46.27%-119.28%63.47%

Marksans Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.

Growth

Compounded Sales Growth
10 Years:13%
5 Years:17%
3 Years:17%
TTM:19%
Compounded Profit Growth
10 Years:16%
5 Years:33%
3 Years:10%
TTM:17%
Stock Price CAGR
10 Years:15%
5 Years:74%
3 Years:69%
1 Year:79%
Return on Equity
10 Years:18%
5 Years:19%
3 Years:17%
Last Year:16%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 3:11 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital39394141414141414141454545
Reserves34903264013924305025958461,1611,7002,0202,236
Borrowings1761731011001101181003034111123244198
Other Liabilities152188207180209142160236307323322372432
Total Liabilities4014906767227527318029021,2281,6362,1902,6812,911
Fixed Assets156146166270267279270303309428486776787
CWIP0000000012310911
Investments000000000012715
Other Assets2453445104524844515335999071,2051,6941,8692,098
Total Assets4014906767227527318029021,2281,6362,1902,6812,911

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +39651553114502723317999237230
Cash from Investing Activity +-5-4-33-123-21-39-13-60-45-84-259-141
Cash from Financing Activity +-40-2917-58-33-21-114-1580198-69
Net Cash Flow-731138-150-1015-7601189417621

Free Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow-100.00-107.00-55.0084.0036.00-65.00-40.0032.00162.00306.00148.00217.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days10998848911871647872978276
Inventory Days112102107120151152215155248216192217
Days Payable818388851295478711031029194
Cash Conversion Cycle141118103124140169202163217211183199
Working Capital Days3748559513011713394110138133138
ROCE %43%37%44%23%4%10%18%25%38%23%22%21%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters48.25%48.25%48.25%48.25%48.60%49.00%43.85%43.85%43.85%43.85%43.85%43.87%
FIIs2.64%2.59%3.46%4.04%4.06%4.23%15.11%14.90%15.07%15.55%15.57%18.59%
DIIs0.53%0.41%0.47%0.94%0.95%0.96%1.46%3.65%4.02%4.76%5.17%3.75%
Public48.58%48.75%47.82%46.77%46.38%45.79%39.57%37.60%37.06%35.81%35.40%33.77%
No. of Shareholders2,01,4512,14,9982,20,0902,21,3592,17,7432,13,1231,98,3821,88,4472,07,9372,37,3772,54,6992,35,500

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Quant Small Cap Fund12,641,2591.88210.29232,7112024-12-295332.17%
UTI Aggressive Hybrid Fund2,078,2530.4621.94232,7112024-12-29793.06%
UTI Large & Mid Cap Fund1,082,6110.5811.43232,7112024-12-29365.22%
UTI Retirement Fund1,049,4990.2811.08232,7112024-12-29350.99%
Motilal Oswal Nifty Microcap 250 Index Fund225,7770.663.76232,7112024-12-29-2.98%
UTI Healthcare Fund232,7110.322.46232,7112024-12-290%
Motilal Oswal S&P BSE Healthcare ETF2,6910.490.04232,7112024-12-29-98.84%
Groww Nifty Total Market Index Fund5570.020.01232,7112024-12-29-99.76%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue1.001.001.001.001.00
Basic EPS (Rs.)6.926.414.515.762.86
Diluted EPS (Rs.)6.926.414.515.762.86
Cash EPS (Rs.)8.597.005.666.713.60
Book Value[Excl.RevalReserv]/Share (Rs.)46.0338.9529.8822.1215.86
Book Value[Incl.RevalReserv]/Share (Rs.)46.0338.9529.8822.1215.86
Revenue From Operations / Share (Rs.)48.0540.8736.4233.6227.71
PBDIT / Share (Rs.)11.238.807.358.464.70
PBIT / Share (Rs.)9.597.656.257.584.05
PBT / Share (Rs.)9.357.456.057.383.84
Net Profit / Share (Rs.)6.955.854.565.832.95
NP After MI And SOA / Share (Rs.)6.925.884.565.832.95
PBDIT Margin (%)23.3721.5220.1725.1616.97
PBIT Margin (%)19.9618.7217.1622.5314.62
PBT Margin (%)19.4518.2316.6021.9513.85
Net Profit Margin (%)14.4614.3212.5317.3310.64
NP After MI And SOA Margin (%)14.4014.3712.5317.3310.64
Return on Networth / Equity (%)15.1915.2515.5326.9018.98
Return on Capital Employeed (%)18.9718.7519.9333.3524.62
Return On Assets (%)11.7012.1511.3919.4213.37
Total Debt / Equity (X)0.010.020.030.020.02
Asset Turnover Ratio (%)0.890.961.040.730.61
Current Ratio (X)4.784.913.373.022.59
Quick Ratio (X)3.193.492.181.671.54
Inventory Turnover Ratio (X)1.211.351.301.741.14
Dividend Payout Ratio (NP) (%)7.223.815.471.7124.43
Dividend Payout Ratio (CP) (%)5.843.194.411.4920.01
Earning Retention Ratio (%)92.7896.1994.5398.2975.57
Cash Earning Retention Ratio (%)94.1696.8195.5998.5179.99
Interest Coverage Ratio (X)45.4343.6735.6143.3622.02
Interest Coverage Ratio (Post Tax) (X)29.1130.0723.1230.8714.81
Enterprise Value (Cr.)6244.012540.861577.141869.83507.17
EV / Net Operating Revenue (X)2.871.371.061.360.44
EV / EBITDA (X)12.276.375.245.402.63
MarketCap / Net Operating Revenue (X)3.151.721.251.490.50
Retention Ratios (%)92.7796.1894.5298.2875.56
Price / BV (X)3.331.831.552.310.89
Price / Net Operating Revenue (X)3.151.721.251.490.50
EarningsYield0.040.080.100.110.21

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Marksans Pharma Ltd as of December 31, 2024 is: 313.55

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of December 31, 2024, Marksans Pharma Ltd is Undervalued by 8.87% compared to the current share price 288.00

Intrinsic Value of Marksans Pharma Ltd as of December 31, 2024 is: 372.81

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of December 31, 2024, Marksans Pharma Ltd is Undervalued by 29.45% compared to the current share price 288.00

Last 5 Year EPS CAGR: 18.90%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 25.67%, which is a positive sign.
  2. The company has higher reserves (825.62 cr) compared to borrowings (124.46 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (369.31 cr) and profit (143.00 cr) over the years.
  1. The stock has a high average Working Capital Days of 102.33, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 164.17, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Marksans Pharma Ltd:
    1. Net Profit Margin: 14.46%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 18.97% (Industry Average ROCE: 16.01%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 15.19% (Industry Average ROE: 15.93%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 29.11
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 3.19
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 37.7 (Industry average Stock P/E: 45.36)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.01
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Marksans Pharma Ltd. is a Public Limited Listed company incorporated on 16/04/1992 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24110MH1992PLC066364 and registration number is 066364. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 658.29 Cr. and Equity Capital is Rs. 40.93 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals11th Floor, Grandeur, Mumbai Maharashtra 400053companysecretary@marksanspharma.com
http://www.marksanspharma.com
Management
NamePosition Held
Mr. Mark SaldanhaChairman & Managing Director
Mrs. Sandra SaldanhaWhole Time Director
Mr. Varddhman V JainWhole Time Director
Dr. Sunny SharmaNon Executive Director
Mr. Seetharama R BuddharajuIndependent Director
Mr. Digant Mahesh ParikhIndependent Director
Mr. Abhinna Sundar MohantyIndependent Director
Mrs. Shailaja VardhanIndependent Director

FAQ

What is the latest intrinsic value of Marksans Pharma Ltd?

The latest intrinsic value of Marksans Pharma Ltd as on 31 December 2024 is ₹313.55, which is 8.87% higher than the current market price of ₹288.00. The stock has a market capitalization of 13,042 Cr. and recorded a high/low of 359/126 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹2,236 Cr and total liabilities of ₹2,911 Cr.

What is the Market Cap of Marksans Pharma Ltd?

The Market Cap of Marksans Pharma Ltd is 13,042 Cr..

What is the current Stock Price of Marksans Pharma Ltd as on 31 December 2024?

The current stock price of Marksans Pharma Ltd as on 31 December 2024 is 288.

What is the High / Low of Marksans Pharma Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Marksans Pharma Ltd stocks is 359/126.

What is the Stock P/E of Marksans Pharma Ltd?

The Stock P/E of Marksans Pharma Ltd is 37.7.

What is the Book Value of Marksans Pharma Ltd?

The Book Value of Marksans Pharma Ltd is 50.3.

What is the Dividend Yield of Marksans Pharma Ltd?

The Dividend Yield of Marksans Pharma Ltd is 0.21 %.

What is the ROCE of Marksans Pharma Ltd?

The ROCE of Marksans Pharma Ltd is 20.6 %.

What is the ROE of Marksans Pharma Ltd?

The ROE of Marksans Pharma Ltd is 16.5 %.

What is the Face Value of Marksans Pharma Ltd?

The Face Value of Marksans Pharma Ltd is 1.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Marksans Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE